Navigation Links
Response Genetics Reports Second Quarter 2007 Financial Results
Date:8/19/2007

dividends 6,097,579 -

Deferred revenue, net of current

portion 3,320,000 1,621,489

Total liabilities 13,762,049 8,811,527

Commitments and contingencies

Stockholders' equity (deficit)

Series B Convertible Preferred

Stock, $0.01 par value; 1,038,048

issued and outstanding (liquidation

preference of $9 per share, or

$9,342,432 plus accrued but unpaid

dividends) at December 31, 2006 10,380 -

Series A Junior Convertible

Preferred Stock, $0.01 par value;

500,000 issued and outstanding

(liquidation preference of $5 per

share, or $2,500,000) at December

31, 2006 5,000 -

Common stock, $0.01 par value;

20,000,000 and 50,000,000 shares

authorized; 2,726,320 and

10,239,256 shares issued and

outstanding 27,263 102,393

Additional paid-in capital 9,722,273 34,311,892

Accumulated deficit (15,267,284) (18,509,649)

Accumulated other comprehensive

income (loss) - (4,208)

Total stockholders' (deficit)

equity (5,502,368) 15,900,428

Total liabilities and stockholders'

(deficit) equity $ 8,259,681 $ 24,711,955

RESPONSE GENETICS, INC.

UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS

Three Months Ended Six Months

June 30, Ended June 30,

2006 2007 2006 2007

Revenue $ 738,150 $ 1,495,618 $ 2,007,125
'/>"/>

SOURCE Response Genetics, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Performance of Ad-A-Gene Cyclic AMP Response Element-Nitroreductase (CRE-NTR): an adenoviral vector gene delivery system
2. FLIPR Calcium 3 Assay Kit - An Optimal No-Wash Fluorescence Calcium Indicator Reagent for Non-Optimal Calcium Responses
3. IT critical in pandemic response, but many are not paying attention
4. Quick response manufacturing and biotech
5. Wisconsin court affirms damages in Innogenetics, Abbott patent case
6. Third Wave licenses Innogenetics tech to settle lawsuit
7. Symposium examines the effect of race on genetics and disease
8. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
9. Sonic Foundry reports GAAP loss as Q2 revenues rise
10. Fiserv reports $113.5 million in Q1 profit
11. Third Wave reports net loss of $18.9M for 2006
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... Dallas, Texas (PRWEB) July 28, 2014 ... Global and China Lubricant Industry” is a ... and Global Lubricant market. The report introduces ... application, and industry chain structure and industry ... analysis, including China’s domestic market as well ...
(Date:7/28/2014)... 28, 2014 Proove Biosciences , ... be exhibiting data and research conducted through their latest ... Intervention Society’s (ISIS) 22nd Annual Scientific Meeting. The ... Hyatt Regency, in Orlando, Florida. , The ... competence of physicians who care for patients suffering specificity ...
(Date:7/28/2014)... , July 28, 2014 /PRNewswire/ -   JOLT , ... of companies to join its growing portfolio of startups. ... Toronto,s JOLT accelerator, and Cohort ... the roster. Since its launch in ... successfully raised  $7.5M of financing. Now at 23 investments, ...
(Date:7/28/2014)... NEW YORK , July 28, 2014 /PRNewswire/ ... for ConvergeHEALTH by Deloitte , has been ... Data Interchange Standards Consortium, a non-profit working to ... research data, particularly as it relates to electronic ... to continue CDISC,s mission of collaborating with organizations ...
Breaking Biology Technology:Lubricant Market & Adhesion Promoter Industry (Globa, China) Analysis Now Available at DeepResearchReports.com 2Lubricant Market & Adhesion Promoter Industry (Globa, China) Analysis Now Available at DeepResearchReports.com 3Lubricant Market & Adhesion Promoter Industry (Globa, China) Analysis Now Available at DeepResearchReports.com 4Proove Biosciences Exhibits Industry Leading Data and Research at International Spine Intervention Society’s 22nd Annual Scientific Meeting 2JOLT Announces the Next 6 Startups to Join its Summer 2014 Cohort 2JOLT Announces the Next 6 Startups to Join its Summer 2014 Cohort 3ConvergeHEALTH by Deloitte's David Hardison Named Chairman of the Clinical Data Interchange Standards Consortium 2ConvergeHEALTH by Deloitte's David Hardison Named Chairman of the Clinical Data Interchange Standards Consortium 3
... 6 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" ... Phase II study of intravenous REOLYSIN(R) in patients with ... at the 15th Annual Connective Tissue Oncology Society Meeting ... 7th. The poster presentation, entitled "A Phase II Study ...
... . Fuel economy ratings for the new ... www.fueleconomy.gov web site, which Oak Ridge National Laboratory developed ... U.S. Environmental Protection Agency. Nine of the top 10 vehicles ... by the Toyota Prius (51 MPG city; 48 highway). "This ...
... , PARSIPPANY, N.J., Nov. 5 DSM Pharmaceutical Products ... with Galenix, Saint Jean D,Illac, France, where DSM will ... commercial products on a global basis. , DSM and ... drug delivery technologies, based on the strength of Galenix ...
Cached Biology Technology:Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 2Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 3November 2009 story tips from the US Department of Energy's Oak Ridge National Laboratory 2November 2009 story tips from the US Department of Energy's Oak Ridge National Laboratory 3DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 2DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 3
(Date:7/28/2014)... Children,s Research Hospital study found that 73 percent of ... risk of developing metabolic syndrome and related health problems ... appear in the current issue of the journal ... adult survivors of childhood cancer in the study had ... like high blood pressure, abdominal obesity, elevated triglyceride and ...
(Date:7/28/2014)... prevent and treat HIV infection has been problematic until ... can arouse as they get rid of the invaders. ... Institute and the National Institutes of Health (NIH) have ... interferons around the time of infection could have ... research appeared in Nature . , Interferons, ...
(Date:7/27/2014)... study has revealed that nicotine and cotinine, a metabolite ... a certain carcinogen in smoke. , The carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone ... leaves and ultimately ends up in the tobacco smoke. ... liver, where it is activated by a variety of ... has revealed that nicotine can partially interfere with the ...
Breaking Biology News(10 mins):Unhealthy habits more than double risk of metabolic syndrome in childhood cancer survivors 2Unhealthy habits more than double risk of metabolic syndrome in childhood cancer survivors 3Interfering with interferon 2Nicotine found to inhibit DNA-strand break caused by a certain carcinogen in smoke 2
... and metabolism, exerts a strong effect on appetite by ... the hypothalamus, according to a Yale School of Medicine ... regulate the ventral tegmental area (VTA) of the mid-brain ... of metabolic signals in the brain," said the senior ...
... technology for the first time ever to measure sexual arousal rates ... than men on its head. ... we see that there is no difference in the amount of ... arousal," said Dr. Irv Binik, psychology professor and founder and director ...
... of Medicine and Public Health has discovered a new part ... vessels, or angiogenesis. , The finding may help halt ... author on the study, a professor of pharmacology and member ... , The research, published in the Journal of Cell Biology ...
Cached Biology News:Thermal imaging shatters arousal gender gap myth 2New angiogenesis finding may help fight cancer growth 2New angiogenesis finding may help fight cancer growth 3New angiogenesis finding may help fight cancer growth 4
Normal serum collected from healthy Kunming mice....
Request Info...
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
QML offers standard and customized paraffin embedded tissue blocks....
Biology Products: